10532201

2005-06-27

U.S. Present and Trademark Reduction Act of 1995, no persons are required to report to a collection of the Trademark Cifice, U.S. CREATEMENT OF COMMENCE.
Under the Paperwork Reduction Act of 1995, no persons are required to regarded to a collection of information unless in contrast, a wait CMS control for the collection of information unless in contrast, a wait CMS control for the collection of information unless in contrast, a wait CMS control for the collection of information unless in contrast, a wait CMS control for the collection of information unless in CMS control for the collection of the co Application Number

Filing Date

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)			LHPFI	First Named inventor Mandola 6			Ad Ct di.					
			Art Ur	Art Unit		1634						
			Examiner Name		Not Assigned							
				Attom	Attorney Docket Number		er	Ţ	UMD-0097			
					U.S.	PATENTS						
Examiner Initial*	examiner Cite No Patent Number Kind Code1		Issue E			of Patentee or Applicant		Rele	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1											
If you wis	h to a	dd additional U.S. Pate	ent citatio	n inform	ation p	lease click	the A	ldo	d button.	_		
			U.S.P.	ATENT	APPLI	CATION P	UBLI	IC.	ATIONS			
Examiner Cite No Publication Number Kind Code1					ne or Patentee or Applicant		Rele	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear				
	1											
If you wis	h to a	dd additional U.S. Pub	lished Ap	plication	n citatio	n informati	on pk	ea	se click the Ad	butto	on.	
				FOREIG	GN PA1	TENT DOC	UME	N	TS			
Examiner Initial*	Cite No	Foreign Document Number ^g	Country Code ²		Kind Code ⁴	Publication Date	on]	Αр	ame of Patente oplicant of cited ocument	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	T4
	1	WO9963114				1999-12-0	9					×
	2	WO0023112				2000-04-2	7					×
If you wist	h to a	d additional Foreign F	atent Do	cument	citation	informatio	n ple	8\$	e click the Add	butto	n	
	_		NON	PATER	AT LITE	PATURE	nnc	111	MENTS			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10532201		
Filing Date		2005-06-27		
First Named Inventor Mand		dola et al.		
Art Unit		1634		
Examiner Name Not A		Assigned		
Attorney Docket Number		UMD-0097		

Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serfal, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.	Ţŝ
	1	Lenz et al., "A 6 base-pair deletion in the 3 UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in colorectal tumors: A possible candidate gene for colorectal cancer risk", Proceedings of the Annual Meeting of the Annual M	×
	2	Horie et al., "Functional Analysis and DNA Polymorphism of the Tandomly Repeated Sequences in the 5'-terminal Regulatory Region of the Human Gene for Thymidylate Synthese", Cell Structure and Function 1995 20:191-197	×
	3	Kowakami et al., "Identification and Functional Analysis of Single Nucleotide Polymorphism in the Tandem Repeat Sequence of Thymidylatis Synthase Gene", Cancer Research 2003 63(18):0004-5007	×
	4	Park et al., "Thyrridylote synthese gene polymorphism predicts response to capecitabline in advanced colorectal cancer", Int J Colorectal Dis 2002 17:46-49	×
	5	Pullarkat et al., "Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy", The Pharmacogenomics Journal 2001 1:65-70	×
	6		
	7		
If you wisl	to ac	ld additional non-patent literature document citation information please click the Add button	

Ex

EXAMINER SIGNATURE		
	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible, * Applicant is to place a check mark here if English language translation is attached.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		10532201		
ling Date		2005-06-27		
irst Named Inventor Mand		ola et al.		
rt Unit		1634		
xaminer Name Not A		ssigned		
Harris Danies Niverk		1840 0007		

CFRT	IFICA?	TION	STA	TEMEN:

E

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
Information disclosure statement, See 37 CFR 1,97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patient office in a counterpair freeign application, and, to the honoletige of the person signing the certification and in the information disclosure statement was shown to any included designated in 3° JCPR 1.56(c) more than three months prior to the filling of the information disclosure.

See attached certification statement.

- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- X None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

-			
Signature	//Jane Massey Licata//	Date (YYYY-MM-DD)	2007-03-07
Name/Print	Jane Massey Licata	Registration Number	32,257

This collection of information is required by 37 CFR 197 and 1.98. The information is required to obtain or retain a benefit by the public which is to fig and by the USPTO to process) an application. Confidentiality is governed by 53 U.S. C. 122 and 57 R. 14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments not the amount of time you require to complete this form and/or suggestions for medium; the burden, should be sent to the Chief information Officer, U.S. Patent and Tradentic Cficer. U.S. Department of Commence, P.O. 8ex 1469, Usexandria, V.23214-450, D.N.OTS SEME FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Petents, P.O. Box 1449, Alexandria, V.22314-450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-978) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, piesse be advised that: (1) the general authority for the collection of this information is 20, U.S.C. 2(b)(b); (2) Junnishing of the information solicided is voluntary, and (3) the priprical purpose for which the enformation is used by the U.S. Patent and Triadments Ciflies is deprocess and/or contains your submission related to a patent application or patent. If you do not furnish the requested creating the process of the process of the priprical purpose. The process of the pripring purpose is the process of the pripring purpose of the pripring purpose

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system or feconds may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neotiations
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designers, cutting an inspection of records conducted by GSA as part of that servery is responsibility to recomment improvements in records management practices and programs, under authority of 44 LI S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing imspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make referring the purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 125(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 114, as a routine use, to the public if the record was feed in an application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application one to publis inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.